CXCR2 and pancreatic adenocarcinoma: Dual-blockade CCR2 plus CXCR2 with specific antagonists reduces tumor-infiltrating myeloid cells and enhances chemotherapeutic responses in pancreatic adenocarcinoma patients and animal models47.